Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis

International Journal of Colorectal Disease

Volumn 21, Issue 3, 2006, Pages 221-230

  Grabowski, Patricia ^a   Sturm, Isrid ^a   Schelwies, Katharina ^a   Maaser, Kerstin ^a   Buhr, Heinz Johannes ^a   Dörken, Bernd ^a   Zeitz, Martin ^a   Daniel, Peter T ^a   Scherübl, Hans ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Colorectal cancer; Neuroendocrine differentiation; p53 BAX; Prognostic marker

Indexed keywords

BIOLOGICAL MARKER; PROTEIN BAX; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE DISRUPTION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL TIME; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; BCL-2-ASSOCIATED X PROTEIN; COLORECTAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33244486993     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-005-0779-5     Document Type: Article

References (50)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8-29
2. Grizzle WE, Manne U, Jhala NC, Weiss HL (2001) Molecular characterization of colorectal neoplasia in translational research. Arch Pathol Lab Med 125:91-98
3. Midgley R, Kerr D (2001) Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs 10:1011-1019
4. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979-994
5. McLeod HL, Murray GI (1999) Tumour markers of prognosis in colorectal cancer. Br J Cancer 79:191-203
6. Staib L, Link KH, Blatz A, Beger HG (2002) Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2400 patients-monoinstitutional experience. World J Surg 26:59-66
7. Cohen AM, Tremiterra S, Candela F, Thaler HT, Sigurdson ER (1991) Prognosis of node-positive colon cancer. Cancer 67:1859-1861
8. Grabowski P, Mann B, Mansmann U, Lovin N, Foss HD, Berger G, Scherübl H, Riecken EO, Buhr HJ, Hanski C (2000) Expression of SIALYL-Le(x) antigen defined by MAb AM-3 is an independent prognostic marker in colorectal carcinoma patients. Int J Cancer 88:281-286
9. Maaser K, Grabowski P, Sutter AP, Höpfner M, Foss HD, Stein H, Berger G, Gavish M, Zeitz M, Scherübl H (2002) Overexpression of the peripheral benzodiazepine receptor is a relevant prognostic factor in stage III colorectal cancer. Clin Cancer Res 8:3205-3209
10. Schelwies K, Sturm I, Grabowski P, Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B, Daniel PT (2002) Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer 99:589-596
11. Paradiso A, Simone G, Lena MD, Leone B, Vallejo C, Lacava J, Dellapasqua S, Daidone MG, Costa A (2001) Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer 84:651-658
12. Giatromanolaki A, Sivridis E, Stathopoulos GP, Fountzilas G, Kalofonos HP, Tsamandas A, Vrettou E, Scopa C, Polychronidis A, Simopoulos K, Koukourakis MI (2001) Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse. Anticancer Res 21:253-259
13. Bondi J, Bukholm G, Nesland JM, Bukholm IR (2004) Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 112:49-56
14. Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dörken B, Daniel PT (2003) Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21:3391-3401
15. Yang JL, Ow KT, Russell PJ, Ham JM, Crowe PJ (1996) Higher expression of oncoproteins c-myc, c-erb B-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. Ann Surg Oncol 3:574-579
16. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, Trivedi TI (2001) Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 44:523-533
17. Grabowski P, Schindler I, Anagnostopoulos I, Foss HD, Riecken EO, Mansmann U, Stein H, Berger G, Buhr HJ, Scherübl H (2001) Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer. Eur J Gastroenterol Hepatol 13:405-411
18. Grabowski P, Schönfelder J, Ahnert-Hilger G, Foss HD, Heine B, Schindler I, Stein H, Berger G, Zeitz M, Scherübl H (2002) Expression of neuroendocrine markers: A signature of human undifferentiated carcinoma of the colon and rectum. Virchows Arch 441:256-263
19. Hamada Y, Oishi A, Shoji T, Takada H, Yamamura M, Hioki K, Yamamoto M (1992) Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer 69:2641-2646
20. Mori M, Mimori K, Kamakura T, Adachi Y, Ikeda Y, Sugimachi K (1995) Chromogranin positive cells in colorectal carcinoma and transitional mucosa. J Clin Pathol 48:754-758
21. Foley EF, Gaffey MJ, Frierson HF Jr (1998) The frequency and clinical significance of neuroendocrine cells within stage III adenocarcinomas of the colon. Arch Pathol Lab Med 122:912-914
22. Le Douarin NM (1995) From the APUD to the neuroendocrine system: A developmental perspective. In: Scherübl H, Hescheler J (eds) The electrophysiology of neuroendocrine cells. CRC, Boca Raton, pp 3-10
23. Brittan M, Wright NA (2004) Stem cell in gastrointestinal structure and neoplastic development. Gut 53:899-910
24. Johnson LR (1988) Regulation of gastrointestinal mucosal growth. Physiol Rev 68:456-502
25. Güner D, Sturm I, Hemmati P, Hermann S, Hauptmann S, Wurm R, Budach V, Dörken B, Lorenz M, Daniel PT (2003) Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 103:445-454
26. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299
27. Daniel PT, Schulze-Osthoff K, Belka C, Güner D (2003) Guardians of cell death: The Bcl-2 family proteins. Essays Biochem 39:73-88
28. Daniel PT (2000) Dissecting the pathways to death. Leukemia 14:2035-2044
29. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K (2001) The kiss of death: Promises and failures of death receptors and ligands in cancer therapy. Leukemia 15:1022-1032
30. Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, Dörken B, Daniel PT (2001) Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 20:2749-2760
31. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489
32. Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT (1999) Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17:1364-1374
33. Hamilton SR, Aaltonen LA (2000) Pathology and genetics of tumours of the digestive system. World Health Organization classification of tumours. IARC, Lyon
34. Sturm I, Papadopoulos S, Hillebrand T, Benter T, Luck HJ, Wolff G, Dörken B, Daniel PT (2000) Impaired BAX protein expression in breast cancer: Mutational analysis of the BAX and the p53 gene. Int J Cancer 87:517-521
35. Grizzle WE, Manne U, Weiss HL, Jhala N, Talley L (2002) Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1). Int J Cancer 97:403-409
36. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B, Daniel PT (2001) Analysis of p53/BAX/ p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: High BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 19:2272-2281
37. de Bruine AP, Wiggers T, Beek C, Volovics A, von Meyenfeldt M, Arends JW, Bosman FT (1993) Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer 54:765-771
38. Vortmeyer AO, Lubensky IA, Merino MJ, Wang CY, Pham T, Furth EE, Zhuang Z (1997) Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 89:1448-1453
39. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
40. Öberg K (1994) Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival. Ann N Y Acad Sci 733:46-55
41. Wulbrand U, Wied M, Zofel P, Göke B, Arnold R, Fehmann H (1998) Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 28:1038-1049
42. Nilsson O, Wangberg B, McRae A, Dahlstrom A, Ahlman H (1993) Growth factors and carcinoid tumours. Acta Oncol 32:115-124
43. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T (2000) Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60:4573-4581
44. Nilsson O, Wangberg B, Kolby L, Schultz GS, Ahlman H (1995) Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int J Cancer 60:645-651
45. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Flejou J, Degott C (1998) Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32:133-138
46. Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ, Streuli CH (2002) Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 277:27643-27650
47. Ahmad T, Farnie G, Bundred NJ, Anderson NG (2004) The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem 279:1713-1719
48. Höpfner M, Sutter AP, Gerst B, Zeitz M, Scherübl H (2003) A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 89:1766-1775
49. Calender A (2000) Molecular genetics of neuroendocrine tumors. Digestion 62(Suppl 1):3-18
50. Lohmann DR, Funk A, Niedermeyer HP, Haupel S, Hofler H (1993) Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B Cell Pathol Incl Mol Pathol 64:293-296